Completed PHASE2 INTERVENTIONAL 2-arm NCT01183221

The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders

Sponsor: Alexander Kolevzon

Updated 7 times since 2017 Last updated: Mar 22, 2021 Started: Jun 18, 2010 Primary completion: Apr 25, 2014 Completion: Apr 25, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates ASD and Autism and is currently completed. Alexander Kolevzon leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2021 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed · Phase: NA → PHASE2
Jan 2021 — May 2021 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status NA
Jan 2017 — Feb 2017 [monthly]

Unknown Status NA

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexander Kolevzon

Data source: Icahn School of Medicine at Mount Sinai

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States